The efficacy of T-DXd was also evaluated in two HER2-low gastric cancer exploratory cohorts, including patients with IHC 2+/ISH− (cohort 1, n = 20), or IHC 1+ (cohort 2, n = 24) [32]. This evidence concerns the gene ERBB2 and gastric cancer.